ClinicalTrials.gg
RecruitingNCT07228273Updated Oct 20, 2026

Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia

A Phase 2 interventional study of Biospecimen Collection and Bone Marrow Aspiration in Acute Myeloid Leukemia and Myelodysplastic Syndrome, sponsored by OHSU Knight Cancer Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by OHSU Knight Cancer Institute · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Oct 20, 2026Interventions changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 191 studies testing fludarabine in Leukemia, Myeloid, Acute — 34 open to participants now, 49 under way, 4 of them phase 3. fludarabine · Leukemia, Myeloid, Acute.

Planned enrollment
36th of 188
102 · median 47
Started
2025
with 6 others
Phase 2
96 of 191
20 open now
Primary completion
2029-06
later than 36 of 48 live
Registered
180th of 191
by date
Lead sponsor
4 of 191
OHSU Knight Cancer Institute

Among the 191 studies testing fludarabine in Leukemia, Myeloid, Acute, this one is the 36th largest by planned enrollment of the 188 interventional ones that give a count, is one of 7 that started in 2025, is one of 96 in phase 2, reaches primary completion later than 36 of the 48 other live ones, and was the 180th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

34 of the 191 studies testing fludarabine in Leukemia, Myeloid, Acute are open now, in 4 countries. Recruiting first, the newest first:

28 more — sign in →

By country, each count listing its studies:

All 34 open studies →

About fludarabine

fludarabine: first FDA approval 1991 (FLUDARA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 191 studies testing fludarabine in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

This phase II trial compares induction and consolidation therapy with fludarabine, cytarabine, idarubicin, and venetoclax to cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of acute myeloid leukemia (AML). Patients with AML often receive induction and consolidation therapy. Induction therapy is given first to get the patient's AML under control (remission). Consolidation therapy is given after the cancer has disappeared following the initial therapy. Consolidation therapy is used to kill any cancer cells that may be left in the body. Chemotherapy drugs, such as fludarabine, cytarabine, idarubicin, and daunorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving fludarabine, cytarabine, idarubicin, and venetoclax for induction and consolidation therapy may be more effective in treating AML.

Read the detailed description

PRIMARY OBJECTIVE:

I. Assess the efficacy of treatment based on rates of measurable residual disease negative composite complete remission (CRc-MRD-) determined using multiparameter flow cytometry (MFC).

SECONDARY OBJECTIVES:

I. Assess the efficacy of treatment based on complete response (CR) disease remission.

II. Assess the efficacy of treatment based on overall clinical response. III. Assess the safety of treatment. IV. Assess survival in the absence of treatment failure, hematologic relapse, or progressive disease.

V. Assess patient survival after commencing study therapy. VI. Assess the delay in hematopoietic stem cell transplant (HSCT) referral and consultation for transition to HSCT.

VII. Assess the efficacy of treatment based on transitioning to HSCT. VIII. Assess disease response after transplant among participants who proceed to HSCT.

IX. Assess risk of post-transplant infection among participants who proceed to HSCT.

X. Assess risk of post-transplant graft versus host disease (GVHD) among participants who proceed to HSCT.

XI. Assess survival in the absence of post-HSCT GVHD and relapse among participants who proceed to HSCT.

EXPLORATORY OBJECTIVES:

I. Evaluate the depth of response with measurable residual disease (MRD) testing and compare methods of determining MRD status.

II. Evaluate survival of measurable residual disease negative (MRD-) patients with CR versus CR with partial or incomplete hematologic recovery.

III. Assess participant quality of life (QoL) using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C30).

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM 1:

INDUCTION: Patients receive cytarabine IV on days 1-7 and daunorubicin (or idarubicin per treating physician's discretion) IV on days 1-3 of each cycle. Cycles repeat every 28 days for up to 1 cycle in the absence of disease progression or unacceptable toxicity. Patients achieving CR, CRh, CRi, or MLFS after one induction cycle proceed to consolidation. Patients achieving PR after one induction cycle may proceed to consolidation at the investigator's discretion. Patients with ≥ 5% blasts after one induction cycle may receive a second cycle of induction therapy. Patients with TKD3 mutation receive a FLT3 inhibitor on study.

CONSOLIDATION: Patients receive fludarabine IV over 30 minutes and cytarabine IV over 4 hours on days 2, 3, and 4 of each cycle, idarubicin IV over 15-30 minutes on days 4, 5, and 6 of either cycles 3 and 6 or cycles 4 and 7, and venetoclax PO QD on days 3-9 of each cycle. Cycles repeat every 28 days for up to 6 post-induction cycles in the absence of disease progression or unacceptable toxicity.

ARM 2:

INDUCTION: Patients receive cytarabine IV on days 1-7 and daunorubicin IV on days 1-3 of each cycle. Cycles repeat every 28 days for up to 1 cycle in the absence of disease progression or unacceptable toxicity. Patients achieving CR, CRh, CRi, or MLFS after one induction cycle proceed to consolidation. Patients achieving PR after one induction cycle may proceed to consolidation at the investigator's discretion. Patients with ≥ 5% blasts after one induction cycle may receive a second cycle of induction therapy.

CONSOLIDATION: Participants receive cytarabine IV over 3 hours twice daily (BID) on days 1, 3, and 5 of each cycle. Cycles repeat every 28 days for up to 4 post-induction cycles in the absence of disease progression or unacceptable toxicity.

Additionally, all patients undergo echocardiography (ECHO) or multigated acquisition (MUGA) scan during screening and on study as clinically indicated. Patients also undergo bone marrow aspiration and biopsy and blood sample collection throughout the trial.

After completion of study treatment, patients are followed up at 30 days and then every 3 months for 2 years.

03

Conditions studied

  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to comprehend the nature of the study and provide written
  • Age 18 to ≤ 65 years (yrs), at the time of consent
  • All gender identities, races, or ethnicities are eligible
  • Newly documented, previously untreated diagnosis of AML or myelodysplastic syndrome (MDS) with marrow blasts ≥ 10%, in agreement with 2022 European LeukemiaNet criteria (ELN22)

    • Leukapheresis and treatment with cytarabine or hydroxyurea prior to study initiation is permitted for cytoreduction in patients with proliferative disease. NOTE: Treatment with cytarabine is limited to up to 2 grams total at least 14 days prior to starting on protocol defined therapy
  • (ECOG) performance status of 0-1
  • Willingness to undergo hematopoietic stem cell transplant ()
  • Ability to take medications by mouth or feeding tube
  • Adequate hematologic and organ function
  • Institutional standards, (NYHA) criteria for cardiac function
  • Calculated (according to the Cockcroft-Gault equation) > 40 mL/min
  • (AST) (serum glutamic oxaloacetic transaminase [SGOT]) ≤ 3 x (ULN), unless considered due to leukemic involvement
  • Alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) ≤ 3 x ULN, unless considered due to leukemic involvement
  • Total ≤ 1.5 x ULN, unless due to Gilbert's disease or leukemic involvement
  • Willing and able to

    • Adhere to study schedule of activities and lifestyle restrictions while on treatment;
    • Provide bone marrow (BM) aspirate and core samples; AND
    • Accept supportive and prophylactic care for hematologic toxicities, infection, and immediate sequelae, including transfusions
  • Negative pregnancy test within 3 days of start of treatment for persons of (PCBP)
  • Based on animal studies and the known pharmacology of the study drugs, PCBP and sperm-producing participants who are sexually active with a PCBP must comply with study requirements for

    • PCBP (participants and PCBP partners of participants) must agree to use an approved contraception and to refrain from donating / cryopreserving ova from cycle (C) 1 day (D) 1 until 6 months following the last dose of study treatment
    • Participants who produce viable sperm and who have intercourse with PCBP must agree to use an approved contraception method and to refrain from donating sperm from C1D1 until 3 months following the last dose of study treatment

Exclusion criteria

Exclusion Criteria:

  • Documented t(15;17) (acute promyelocytic leukemia [APL]), and/or mutation(s) to FLT3 ITD or core binding factor (CBF). Point mutations within the tyrosine kinase domain (FLT3 TKD) are allowed
  • Another active within the previous 5 years, except treated early stage carcinomas of the skin, or at the investigator's discretion
  • Known, active central nervous system (CNS) involvement with AML
  • Recent and significant medical interventions, such as major surgery within 28 days of start of treatment
  • or stem cell transplant within 100 days of start of treatment
  • Currently receiving therapy or chemotherapy within 28 days, or 5 half-lives, whichever is longer, with the exception of hydroxyurea or cytarabine for cytoreduction purposes
  • Prior treatment with a BCL 2 inhibitor within 12 months prior to the start of treatment
  • Use of strong or moderate inducers or inhibitors or P-gp inhibitors within 2 days or 3 half-lives, whichever is longer, prior to start of treatment with venetoclax or at the discretion of the investigator if dose reductions, based on the interaction, have been specified
  • History of allergic response to any of the interventional agents or any in the formulations
  • Inadequate organ function, including the following (or at the discretion of the investigator):

    • History of (NYHA) class III or IV congestive heart failure or (LVEF) \< 40% by echocardiogram (ECHO) or multigated acquisition (MUGA) scan
    • Unstable/uncontrolled angina pectoris, history of severe and/or uncontrolled ventricular arrhythmias, or history of myocardial infarction within the last 6 months
    • A white blood cell count (WBC) > 25 x 10\^⁹/L
  • Known dysphagia in the absence of a feeding tube, short-gut syndrome, or other conditions or causes that would affect the ingestion and/or gastrointestinal absorption of drugs administered orally
  • Active hepatic disorder or documented positive or C virus (HBV/, respectively) status, except in cases of undetectable HBV/HCV viral load for at least 3 months prior to the start of treatment. (Hepatitis B or C testing is not required for eligibility assessment.)
  • Individuals with positive serology for (HIV) who are undergoing treatment with highly active antiretroviral therapy (HAART) (or another therapy that may interfere with metabolism of study agents) are not eligible. If the HIV infection is controlled with another medication type or if an acceptable alternative HIV treatment can be substituted for HAART, enrollment may proceed
  • Uncontrolled infection. Participants with controlled infection must be afebrile and hemodynamically stable for at least 72 hours prior to start of treatment and must be amenable to alternate treatment if current treatment will interact with investigational regimen
  • Psychiatric illness/social situations that would limit compliance with study requirements
  • Unwillingness to stop breastfeeding. Because there is a potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding is not allowed throughout the study for 6 weeks after the last dose of study drug
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
102 participants (estimated)

Study arms

  • Experimental
    Arm 1 (fludarabine, cytarabine, idarubicin, venetoclax)

    See Detailed Description.

    Procedure: Bone Marrow Aspiration · Procedure: Bone Marrow Biopsy · Drug: Cytarabine · Procedure: Echocardiography Test · Drug: Fludarabine · Drug: Idarubicin · Procedure: Multigated Acquisition Scan · Other: Questionnaire Administration · Drug: Venetoclax

  • Active comparator
    Arm 2 (cytarabine, daunorubicin or idarubicin)

    See Detailed Description

    Procedure: Biospecimen Collection · Procedure: Bone Marrow Aspiration · Procedure: Bone Marrow Biopsy · Drug: Cytarabine · Drug: Daunorubicin · Procedure: Echocardiography Test · Drug: Idarubicin · Procedure: Multigated Acquisition Scan · Other: Questionnaire Administration · Device: Device FLT3 Inhibitor

Interventions

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • ProcedureBone Marrow Aspiration

    Undergo bone marrow aspiration

  • ProcedureBone Marrow Biopsy

    Undergo bone marrow biopsy

    Also known as: Biopsy of Bone Marrow, Biopsy, Bone Marrow

  • Given IV

    Also known as: .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453

  • Given IV

    Also known as: Daunomycin, Daunorrubicina, DNR, Leukaemomycin C, Rubidomycin, Rubomycin C

  • ProcedureEchocardiography Test

    Undergo ECHO

    Also known as: EC, Echocardiography

  • Given IV

    Also known as: Fluradosa

  • Given IV

    Also known as: 4-Demethoxydaunomycin, 4-Demethoxydaunorubicin, 4-DMDR

  • ProcedureMultigated Acquisition Scan

    Undergo MUGA scan

    Also known as: Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning

  • OtherQuestionnaire Administration

    Ancillary studies

  • Given PO

    Also known as: ABT 199, ABT-0199, ABT-199, ABT199, GDC 0199, GDC-0199, GDC0199, RG7601, Venclexta, Venclyxto

  • DeviceDevice FLT3 Inhibitor

    FLT3 Inhibitor, Receptor-Type Tyrosine-Protein Kinase FLT3 Protein Inhibitor. Given FLT3 inhibitor

  • (1S,3S)-3-Acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-6,11-dioxo-1-naphthacenyl-3-amino-2,3,6-trideoxy-alpha-L-hexopyranoside, (7S-cis)-9-Acetyl-7-\[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy\]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione, 4-Demethoxydaunomycin, 4-demethoxydaunorubicin, 4-Demethoxydaunorubicin, 4-DMDR, 58957-92-9, IDARUBICIN, Idarubicin, idarubicin, Idarubicin. Given IV

06

What researchers measure

Primary outcomes

  1. Percentage of participants achieving measurable residual disease negative composite complete remission (CRc-MRD-)

    Will be defined as the achievement of both measurable disease negative (MRD-) by multiparameter flow cytometry and complete response (CR), CR with partial hematologic recovery (CRh), or CR with incomplete blood count recovery (CRi). Participants who do not qualify as efficacy-evaluable (usually due to early death or withdrawal because of toxicity) will be considered non-responders. A point estimate and 95% exact confidence interval (CI) for CRc MRD- will be computed for each arm (and time point) separately and the CRc MRD- rate will be statistically compared across arms with Fisher's exact test at 3 timepoints: end of induction, end of the first consolidation cycle, and end of treatment. A Hochberg multiplicity adjustment will be applied to the p-values from these 3 Fisher exact tests to control the family wise error rate (at α=0.05) for between-arm comparisons of the primary endpoint. CRc MRD- status at each of the above-specified time points will be modeled with logistic regression.

    Time frame: Up to 30 days post last dose of study drug

Secondary outcomes

  1. Percentage of participants achieving CR

    Will be computed for each arm separately in both the safety set and the efficacy set. Will be presented with a point estimate and exact binomial 95% CI. will also be modeled with logistic regression with baseline patient and disease features as predictors and results considered hypothesis-generating.

    Time frame: Up to 30 days post last dose of study drug

  2. Percentage of participants achieving composite complete remission (CRc)

    CRc will be defined as the achievement of CR, CRh, or CRi. Will be computed for each arm separately in both the safety set and the efficacy set. Will be presented with a point estimate and exact binomial 95% CI. will also be modeled with logistic regression with baseline patient and disease features as predictors and results considered hypothesis-generating.

    Time frame: Up to 30 days post last dose of study drug

  3. Percentage of participants achieving an overall response (ORR)

    Will be defined as the proportion of participants who attain a partial remission (PR) or better (i.e., CR, CRh, CRi, morphologic leukemia-free state, or PR) after receiving study treatment. Will be computed for each arm separately in both the safety set and the efficacy set and presented with point estimate and exact binomial 95% CI. Will also be modeled with logistic regression with baseline patient and disease features as predictors and results considered hypothesis-generating.

    Time frame: Up to 30 days post last dose of study drug

  4. Incidence of treatment-emergent grade ≥ 3 adverse events (AEs)

    Will be assessed using Common Terminology Criteria for Adverse Events version 5.0. The incidence of specific grade ≥ 3 AEs will be reported with frequencies and percentages, at the overall participant level and by grade, attribution (i.e., a separate table for treatment-related AEs), and seriousness (i.e., separate tables for serious adverse events).

    Time frame: Up to 30 days after the last dose of any study drug

  5. Event free survival (EFS)

    If these events do not occur prior to end of study (EOS), participant is censored at date of last disease assessment. Will be estimated for the efficacy set using the Kaplan-Meier method, with median EFS and EFS rates at common landmark times (e.g., 6 months, 1 year, 2 years) presented with 95% log-log CIs. Cox models will be fit to EFS to assess the impact of baseline patient and disease features, with model results (i.e., hazard ratios and Wald test p-values) interpreted as hypothesis-generating.

    Time frame: From cycle (C)1 day(D)1 to first occurrence of treatment failure, disease progression, or death due to any cause, assessed up to 2 years

  6. Overall survival (OS)

    If no death occurs prior to EOS, participant is censored at last known alive date. Will be computed in each arm for both the safety set and the efficacy set. Will be estimated with the Kaplan-Meier method. Median OS and OS rates at common landmark times (e.g., 1 year, 2 years) will be estimated with 95% log-log CIs. For each of the two specified analysis sets, Cox models will be fit to OS to assess the impact of baseline patient and disease features and hematopoietic stem cell transplant (HSCT) as a time-dependent covariate, with results considered hypothesis generating.

    Time frame: From C1D1 to date of death due to any cause, assessed up to 2 years

  7. Time to HSCT referral

    Within each arm and for both the safety and efficacy sets (separately), cumulative incidence functions (CIFs) will be used to estimate the post-C1D1 time to HSCT referral with death considered a competing risk and patients lacking these bone marrow transplant (BMT) preparation related events being censored at EOS. Between arm differences in time to each of these HSCT-preparatory events will be computed using Gray's test. For each participant cohort (i.e., within each arm for both the safety and efficacy sets), the proportion of patients who are referred to HSCT will be computed with point estimate and 95% exact binominal CI. Fisher's exact test will be employed to test for an association between the occurrence of each HSCT-preparatory event and study arm.

    Time frame: Up to 2 years after end of study treatment

  8. Time to completed consult for HSCT

    Within each arm and for both the safety and efficacy sets (separately), CIFs will be used to estimate the post-C1D1 time to HSCT consultation with death considered a competing risk and patients lacking these BMT preparation related events being censored at EOS. Between arm differences in time to each of these HSCT-preparatory events will be computed using Gray's test. For each participant cohort (i.e., within each arm for both the safety and efficacy sets), the proportion of patients who complete a HSCT consult will be computed with point estimate and 95% exact binominal CI. Fisher's exact test will be employed to test for an association between the occurrence of each HSCT-preparatory event and study arm.

    Time frame: Up to 2 years after end of study treatment

  9. Percentage of participants who transition to HSCT

    Will be computed on both the safety and efficacy sets within each study arm. Besides a point estimate and exact binominal 95% CI for the proportion of patients proceeding to HSCT at any time or within 100 days of commencing study therapy, time-to-HSCT (measured from C1D1) will be estimated within each arm using a CIF, tested across arms with Gray's test, and modeled with Fine-Gray regressions (with baseline patient and disease features as predictors and results considered as hypothesis-generating). For these analyses, pre-HSCT deaths will be considered a competing risk and patients alive but not transplanted will be censored when going off-study.

    Time frame: Up to 2 years after end of study treatment

  10. Cumulative incidence of HSCT

    Will be computed on both the safety and efficacy sets within each study arm. Besides a point estimate and exact binominal 95% CI for the proportion of patients proceeding to HSCT at any time or within 100 days of commencing study therapy, time-to-HSCT (measured from C1D1) will be estimated within each arm using a CIF, tested across arms with Gray's test, and modeled with Fine-Gray regressions (with baseline patient and disease features as predictors and results considered as hypothesis-generating). For these analyses, pre-HSCT deaths will be considered a competing risk and patients alive but not transplanted will be censored when going off-study.

    Time frame: Up to 2 years after end of study treatment

  11. Percentage of participants who are MRD- post-HSCT

    Will be estimated along with an exact binomial 95% CI.

    Time frame: From HSCT day 0 to day +365 post-HSCT

  12. Cumulative incidence of grade 2-3 post-HSCT infections

    Will be assess moderate and severe bacterial, viral, and fungal infections according to Blood and Marrow Transplant Clinical Trials Network criteria. Will be estimated with a CIF (considering death as a competing risk).

    Time frame: From HSCT day 0 to day +100 post-HSCT

  13. Cumulative incidence of grade ≥ II acute graft versus host disease (aGVHD)

    Will be assessed using the Mount Sinai Acute Graft Versus Host Disease International Consortium (MAGIC) criteria. Will be estimated with a CIF (considering death as a competing risk).

    Time frame: From HSCT day 0 to day +365 post-HSCT

  14. Cumulative incidence of grade ≥ 2 (cGVHD)

    Will be assessed using the National Institutes of Health consensus criteria. Will be estimated with a CIF (considering death as a competing risk).

    Time frame: From HSCT day 0 to day +365 post-HSCT

  15. GVHD-free, relapse-free survival (GRFS)

    Will be computed and reported for the transplanted population from the time of transplant to a qualifying event. Data from participants without any of the specified GRFS events will be censored at the date of the last disease assessment or the date of the last GVHD assessment, whichever occurs earlier. GRFS will be presented with a point estimate and exact binomial CI.

    Time frame: From HSCT day 0 to disease relapse, MAGIC grade III-IV aGVHD, cGVHD requiring systemic therapy, death from any cause or last known alive, or day + 365 post-HSCT, whichever occurs earliest

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jun 2029, 42 months after the start.

Of 385 non-industry phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 107. This study's planned 42 months is below that.

Counting every sponsor, half of 442 studies reached it within 60 months; a quarter within 38 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2025
First posted
Nov 14, 2025
StartActual
Dec 12, 2025
Primary completionEst.
Jun 24, 2029
CompletionEst.
Aug 24, 2029
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Interventions
Added Device: Device FLT3 Inhibitor·Drug: Idarubicin. Arm changed Arm 2 (cytarabine, daunorubicin)→Arm 2 (cytarabine, daunorubicin or idarubicin)
Oct 20, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedCumulative incidence of grade ≥ 2 chronic graft versus host disease (cGVHD)Time frame: From HSCT day 0 to day +365 post-HSCT
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedCumulative incidence of grade ≥ 2 chronic graft versus host disease (cGVHD)Time frame: From HSCT day 0 to day +365 post-HSCT
    Interventions Added Device: Device FLT3 Inhibitor·Drug: Idarubicin. Arm changed Arm 2 (cytarabine, daunorubicin)→Arm 2 (cytarabine, daunorubicin or idarubicin)
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07228273
Responsible party
Curtis Lachowiez (Principal Investigator, OHSU Knight Cancer Institute) — Principal investigator
First posted
Nov 14, 2025
Start date
Dec 12, 2025
Primary completion
Jun 24, 2029 (estimated)
Completion
Aug 24, 2029 (estimated)
Last update
Oct 20, 2026

Study contacts

Curtis A Lachowiez
principal investigator · OHSU Knight Cancer Institute

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fludarabine · Venetoclax

Start the discussion